Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315135 | 0.93 | RORC (0.32) | RORCNPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL464531 | 0.83 | RORC (0.49) | RORCNPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL3893600 | 0.78 | RORC (0.46) | RORCNPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL13046493 | 0.75 | MAPT (0.44) | NPC1MAPTRAB9AALDH1A1HPGD | |
| SCHEMBL394967 | 0.74 | NPC1 (0.47) | NPC1MAPTRAB9AALDH1A1HPGD | |
| SCHEMBL429374 | 0.71 | ALDH1A1 (0.52) | ALDH1A1MAOB | |
| SCHEMBL12753477 | 0.70 | RORC (0.35) | RORCMAPTALDH1A1 | |
| SCHEMBL20956396 | 0.67 | RAB9A (0.40) | NPC1MAPTRAB9AALDH1A1HPGD | |
| SCHEMBL20956395 | 0.67 | RAB9A (0.40) | NPC1MAPTRAB9AALDH1A1HPGD | |
| SCHEMBL19179675 | 0.67 | RAB9A (0.40) | NPC1MAPTRAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | RORC 3621/4885NPC1 434/4885MAPT 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.